Tokyo Tape
Sign in
← Nipro

Quarterly report · Q1

8086.TEDINET S100RNZX
Period2023-04-01 → 2023-06-30
Filed2023-08-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 34
MetricValuePeriodScopeSource row
Revenue¥140.6bn2023-04-01 → 2023-06-30Cons.Net sales
Revenue¥545.2bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥127.9bn2022-04-01 → 2022-06-30Cons.Net sales
Operating income¥7.3bn2023-04-01 → 2023-06-30Cons.Operating income
Operating income¥3.0bn2022-04-01 → 2022-06-30Cons.Operating income
Ordinary income¥8.9bn2023-04-01 → 2023-06-30Cons.Ordinary income
Ordinary income¥15.3bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥7.3bn2022-04-01 → 2022-06-30Cons.Ordinary income
Profit before tax¥9.4bn2023-04-01 → 2023-06-30Cons.Income before income taxes
Profit before tax¥9.0bn2022-04-01 → 2022-06-30Cons.Income before income taxes
Net income (owners)¥4.1bn2023-04-01 → 2023-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥4.6bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥5.3bn2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income¥4.4bn2023-04-01 → 2023-06-30Cons.Profit loss
Net income¥5.7bn2022-04-01 → 2022-06-30Cons.Profit loss
Total assets¥1.04Tat 2023-06-30Cons.Assets
Total assets¥1.03Tat 2023-03-31Cons.Assets
Total assets¥947.6bnat 2022-06-30Cons.Total assets (5-year summary)
Total liabilities¥791.5bnat 2023-06-30Cons.Liabilities
Total liabilities¥785.2bnat 2023-03-31Cons.Liabilities
Net assets / equity¥249.2bnat 2023-06-30Cons.Net assets
Net assets / equity¥242.2bnat 2023-03-31Cons.Net assets
Net assets / equity¥217.3bnat 2022-06-30Cons.Net assets (5-year summary)
Cash and deposits¥88.1bnat 2023-06-30Cons.Cash and deposits
Cash and deposits¥89.7bnat 2023-03-31Cons.Cash and deposits
EPS (basic)¥25.142023-04-01 → 2023-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥28.052022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥32.352022-04-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥22.272023-04-01 → 2023-06-30Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥24.852022-04-01 → 2023-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥28.662022-04-01 → 2022-06-30Cons.Diluted earnings per share (5-year summary)
Equity ratio20.5%at 2023-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio20.1%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio21.3%at 2022-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 54
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-04-01 → 2023-06-30¥1.2bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-04-01 → 2023-06-30¥189m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-04-01 → 2023-06-30¥971m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-04-01 → 2023-06-30¥3m
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-06-30−¥14.5bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-06-30−¥14.5bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-06-30−¥8.2bn
jpcrp040300-q1r_E02688-000Medical Treatment Relatedreportable segmentrevenue2023-04-01 → 2023-06-30¥109.6bn
jpcrp040300-q1r_E02688-000Medical Treatment Relatedreportable segmentrevenue external2023-04-01 → 2023-06-30¥108.0bn
jpcrp040300-q1r_E02688-000Medical Treatment Relatedreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥1.6bn
jpcrp040300-q1r_E02688-000Medical Treatment Relatedreportable segmentsegment profit2023-04-01 → 2023-06-30¥11.8bn
jpcrp040300-q1r_E02688-000Medicine Relatedreportable segmentrevenue2023-04-01 → 2023-06-30¥27.8bn
jpcrp040300-q1r_E02688-000Medicine Relatedreportable segmentrevenue external2023-04-01 → 2023-06-30¥17.4bn
jpcrp040300-q1r_E02688-000Medicine Relatedreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥10.3bn
jpcrp040300-q1r_E02688-000Medicine Relatedreportable segmentsegment profit2023-04-01 → 2023-06-30¥3.2bn
jpcrp040300-q1r_E02688-000Pharma Packagingreportable segmentrevenue2023-04-01 → 2023-06-30¥16.6bn
jpcrp040300-q1r_E02688-000Pharma Packagingreportable segmentrevenue external2023-04-01 → 2023-06-30¥15.0bn
jpcrp040300-q1r_E02688-000Pharma Packagingreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥1.6bn
jpcrp040300-q1r_E02688-000Pharma Packagingreportable segmentsegment profit2023-04-01 → 2023-06-30¥566m
—segment totalrevenue2023-04-01 → 2023-06-30¥153.9bn
—segment totalrevenue external2023-04-01 → 2023-06-30¥140.4bn
—segment totalrevenue intersegment2023-04-01 → 2023-06-30¥13.5bn
—segment totalsegment profit2023-04-01 → 2023-06-30¥15.6bn
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-06-30¥155.1bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-06-30¥140.6bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-06-30¥14.5bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-06-30¥15.6bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-06-30¥1.0bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-06-30¥154m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-06-30¥855m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-06-30¥211m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-06-30−¥9.3bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-06-30−¥9.3bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-06-30−¥7.1bn
jpcrp040300-q1r_E02688-000Medical Treatment Relatedreportable segmentrevenue2022-04-01 → 2022-06-30¥99.3bn
jpcrp040300-q1r_E02688-000Medical Treatment Relatedreportable segmentrevenue external2022-04-01 → 2022-06-30¥97.7bn
jpcrp040300-q1r_E02688-000Medical Treatment Relatedreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥1.6bn
jpcrp040300-q1r_E02688-000Medical Treatment Relatedreportable segmentsegment profit2022-04-01 → 2022-06-30¥8.5bn
jpcrp040300-q1r_E02688-000Medicine Relatedreportable segmentrevenue2022-04-01 → 2022-06-30¥23.2bn
jpcrp040300-q1r_E02688-000Medicine Relatedreportable segmentrevenue external2022-04-01 → 2022-06-30¥17.9bn
jpcrp040300-q1r_E02688-000Medicine Relatedreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥5.3bn
jpcrp040300-q1r_E02688-000Medicine Relatedreportable segmentsegment profit2022-04-01 → 2022-06-30¥407m
jpcrp040300-q1r_E02688-000Pharma Packagingreportable segmentrevenue2022-04-01 → 2022-06-30¥13.7bn
jpcrp040300-q1r_E02688-000Pharma Packagingreportable segmentrevenue external2022-04-01 → 2022-06-30¥12.2bn
jpcrp040300-q1r_E02688-000Pharma Packagingreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥1.5bn
jpcrp040300-q1r_E02688-000Pharma Packagingreportable segmentsegment profit2022-04-01 → 2022-06-30¥1.0bn
—segment totalrevenue2022-04-01 → 2022-06-30¥136.2bn
—segment totalrevenue external2022-04-01 → 2022-06-30¥127.7bn
—segment totalrevenue intersegment2022-04-01 → 2022-06-30¥8.4bn
—segment totalsegment profit2022-04-01 → 2022-06-30¥9.9bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-06-30¥137.2bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-06-30¥127.9bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-06-30¥9.3bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-06-30¥10.1bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 446
ItemContextValueUnit
Loss on sale of investment in affiliated companies elCurrentYTDDuration1560000000JPY
Other elPrior1YTDDuration18000000JPY
Other elCurrentYTDDuration105000000JPY
Extraordinary lossPrior1YTDDuration277000000JPY
Extraordinary lossCurrentYTDDuration1930000000JPY
Income before income taxesPrior1YTDDuration9008000000JPY
Income before income taxesCurrentYTDDuration9368000000JPY
Income taxes currentPrior1YTDDuration2459000000JPY
Income taxes currentCurrentYTDDuration2726000000JPY
Income taxes deferredPrior1YTDDuration807000000JPY
Income taxes deferredCurrentYTDDuration2211000000JPY
Income taxesPrior1YTDDuration3267000000JPY
Income taxesCurrentYTDDuration4937000000JPY
Profit lossPrior1YTDDuration5741000000JPY
Profit lossCurrentYTDDuration4430000000JPY
Profit loss attributable to non controlling interestsPrior1YTDDuration466000000JPY
Profit loss attributable to non controlling interestsCurrentYTDDuration330000000JPY
Profit loss attributable to owners of parentPrior1YTDDuration5275000000JPY
Profit loss attributable to owners of parentCurrentYTDDuration4099000000JPY
Profit lossPrior1YTDDuration5741000000JPY
Profit lossCurrentYTDDuration4430000000JPY
Valuation difference on available for sale securities net of tax ociPrior1YTDDuration-875000000JPY
Valuation difference on available for sale securities net of tax ociCurrentYTDDuration-974000000JPY
Deferred gains or losses on hedges net of tax ociPrior1YTDDuration6000000JPY
Deferred gains or losses on hedges net of tax ociCurrentYTDDuration-6000000JPY
Foreign currency translation adjustment net of tax ociPrior1YTDDuration13847000000JPY
Foreign currency translation adjustment net of tax ociCurrentYTDDuration5185000000JPY
Remeasurements of defined benefit plans net of tax ociPrior1YTDDuration-15000000JPY
Remeasurements of defined benefit plans net of tax ociCurrentYTDDuration-69000000JPY
Share of other comprehensive income of associates accounted for using equity method ociPrior1YTDDuration778000000JPY
Share of other comprehensive income of associates accounted for using equity method ociCurrentYTDDuration-51000000JPY
Other comprehensive incomePrior1YTDDuration13741000000JPY
Other comprehensive incomeCurrentYTDDuration4083000000JPY
Comprehensive incomePrior1YTDDuration19483000000JPY
Comprehensive incomeCurrentYTDDuration8514000000JPY
Comprehensive income attributable to owners of the parentPrior1YTDDuration18717000000JPY
Comprehensive income attributable to owners of the parentCurrentYTDDuration8211000000JPY
Comprehensive income attributable to non controlling interestsPrior1YTDDuration765000000JPY
Comprehensive income attributable to non controlling interestsCurrentYTDDuration302000000JPY
Exporting notes receivable discountedPrior1YearInstant－JPY
Exporting notes receivable discountedCurrentQuarterInstant3000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q1r_E02688-000MedicalTreatmentRelatedReportableSegmentsMember97653000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q1r_E02688-000MedicineRelatedReportableSegmentsMember17870000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q1r_E02688-000PharmaPackagingReportableSegmentMember12214000000JPY
Revenues from external customersPrior1YTDDuration_ReportableSegmentsMember127738000000JPY
Revenues from external customersPrior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember154000000JPY
Revenues from external customersPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember127892000000JPY
Revenues from external customersPrior1YTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersPrior1YTDDuration127892000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q1r_E02688-000MedicalTreatmentRelatedReportableSegmentsMember1628000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2023-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-06-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-06-30pass